SRNE vs. GENE, IKT, BCDA, CHRO, ONVO, COEP, TTNP, CELZ, FRTX, and PALI
Should you be buying Sorrento Therapeutics stock or one of its competitors? The main competitors of Sorrento Therapeutics include Genetic Technologies (GENE), Inhibikase Therapeutics (IKT), BioCardia (BCDA), Chromocell Therapeutics (CHRO), Organovo (ONVO), Coeptis Therapeutics (COEP), Titan Pharmaceuticals (TTNP), Creative Medical Technology (CELZ), Fresh Tracks Therapeutics (FRTX), and Palisade Bio (PALI). These companies are all part of the "biological products, except diagnostic" industry.
Sorrento Therapeutics (NASDAQ:SRNE) and Genetic Technologies (NASDAQ:GENE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, community ranking, analyst recommendations and profitability.
Sorrento Therapeutics received 449 more outperform votes than Genetic Technologies when rated by MarketBeat users. Likewise, 71.10% of users gave Sorrento Therapeutics an outperform vote while only 55.33% of users gave Genetic Technologies an outperform vote.
Sorrento Therapeutics has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Comparatively, Genetic Technologies has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500.
Genetic Technologies has lower revenue, but higher earnings than Sorrento Therapeutics.
0.0% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 0.6% of Genetic Technologies shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by company insiders. Comparatively, 6.5% of Genetic Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Genetic Technologies had 11 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 12 mentions for Genetic Technologies and 1 mentions for Sorrento Therapeutics. Genetic Technologies' average media sentiment score of 0.21 beat Sorrento Therapeutics' score of 0.00 indicating that Genetic Technologies is being referred to more favorably in the news media.
Summary
Genetic Technologies beats Sorrento Therapeutics on 6 of the 10 factors compared between the two stocks.
Get Sorrento Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sorrento Therapeutics Competitors List
Related Companies and Tools
